Recent Articles

September 21, 2017 11:46 am
Joanne Van Zuidam
In Phase III HALO studies in chronic and episodic migraine, the monoclonal antibody fremanezumab met all 25 pre-specified study endpoints across both monthly and quarterly dosing regimens.
September 20, 2017 9:33 am
Ryan Bushey
The pharmaceutical company plans on submitting a New Drug Application to the FDA in late 2017.
September 19, 2017 10:13 am
Kenneth Maxik, MBA, MBB, FACHE, Director of Patient Safety, CompleteRx
The rule provides standards for safe handling of hazardous drugs to minimize the risk of exposure to healthcare personnel, patients, and environments.
September 19, 2017 9:49 am
Ryan Bushey
The tool works by measuring immune system biomarkers in blood samples and then uses machine learning algorithms to identify patterns in certain infections.
September 18, 2017 10:35 am
Ryan Bushey
Findings indicated one receptor was associated with successfully clearing a virus in experiments.
September 15, 2017 10:05 am
Melanie Nallicheri, Chief Business Officer and Head of Biopharma at Foundation Medicine
These technologies are helping to realize the vision of precision medicine.
September 14, 2017 10:18 am
Eric Hobbs, CEO, Berkeley Lights, Inc.
Over the past 25 years we have seen the advent of the molecular revolution with genomic profiling and whole genome sequencing. The whole genome project opened the door to understanding the human genome, and we are now applying that understanding to critical areas such as classifying disease by its genomic components.
September 13, 2017 3:26 pm
Sarah Jane Tribble, Kaiser Health News
Over the years, drugmakers have fueled a boom in orphan drugs, which often carry six-figure price tags.
September 13, 2017 8:53 am
Ryan Bushey
Another pharmaceutical company revealed it would initiate a restructuring strategy designed to cut costs and streamline operations.
September 13, 2017 9:53 am
Darcee Strube, Senior Vice President, Dermatology Division, Novella Clinical
Realizing the promise of biologics—protein-based drugs created from genetically modified cells—has been a complex path in dermatology. While further research is needed, the safety and efficacy of biologic treatments are still welcomed by patients and physicians. Biologics are helping patients to see maximum skin clearance and realize an enhanced quality of life.
Subscribe to Drug Discovery & Development